The Mortality Risk of Conventional Antipsychotics in Elderly Patients: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

Journal of the American Medical Directors Association

Volumn 16, Issue 10, 2015, Pages 817-824

  Hulshof, Tessa A ^a,b   Zuidema, Sytse U ^a   Ostelo, Raymond W J G ^b,c   Luijendijk, Hendrika J ^a,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d BAVO Europoort   (Netherlands)

Author keywords

Conventional antipsychotics; Dementia; Elderly; Meta analysis; Mortality

Indexed keywords

CHLORPROMAZINE; CHLORPROTHIXENE; DROPERIDOL; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

AGED; AGING; ATTRIBUTABLE RISK; DELIRIUM; DEMENTIA; HUMAN; INFORMATION PROCESSING; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

AGED; ANTIPSYCHOTIC AGENTS; DELIRIUM; DEMENTIA; HUMANS; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944173974     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.03.015     Document Type: Review

References (43)

1. Lanctot K., Best T., Mittmann N., et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. Clin Psychiatry 1998, 59:549-563.
2. Schneider L., Dagerman K., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. J Am Med Assoc 2005, 294:1934-1943.
3. Pratt N., Roughead E., Salter A., Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: A systematic review. BMC Med Res Methodol 2012, 12:72.
4. Hollis J., Forrester L., Brodaty H., et al. Risk of death associated with antipsychotic drug dispensing in residential aged care facilities. Aust N Z J Psychiatry 2007, 41:751-758.
5. Rossom R., Rector T., Lederle F., Dysken M. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?. J Am Geriatr Soc 2010, 58:1027-1034.
6. Information for healthcare professionals: Conventional antipsychotics US Food and Drug Administration, Available at:, Accessed June 12, 2013. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm.
7. Conventional (typical) antipsychotics: Increased mortality in dementia. MHRA Drug Safety Update, Available at:, Accessed June 12, 2013. http://webarchive.nationalarchives.gov.uk/20141205150130/http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087985.
8. Luijendijk H., De Bruin N., Koolman X. Haloperidol in elderly users: Not a cause of death, but caused by impeding death?. Am J Epidemiol 2013, 177:S1-S181.
9. Maltoni M., Scarpi E., Rosati M., et al. Palliative sedation in end-of-life care and survival: A systematic review. J Clin Oncol 2012, 30:1378-1383.
10. Mercadante S., Fulfaro F., Casuccio A. Pattern of drug use by advanced cancer patients followed at home. J Palliat Care 2001, 17:37-40.
11. Lonergan E., Luxenberg J., Colford J., Birks J. Haloperidol for agitation in dementia (Review). Cochrane Libr 2002, 12:1-42.
12. Hasegawa N., Hashimoto M., Yuuki S., et al. Prevalence of delirium among outpatients with dementia. Int Psychogeriatr 2013, 25:1877-1883.
13. Sandberg O., Gustafson Y., Brannstrom B., Bucht G. Prevalence of dementia, delirium and psychiatric symptoms in various care settings for the elderly. Scand J Soc Med 1998, 26:56-62.
14. Friedman J., Soleimani L., McGonigle D., et al. Pharmacological treatments of non-substance-withdrawal delirium: A systematic review of prospective trials. Am J Psychiatry 2014, 171:151-159.
15. The Grading of Recommendations Assessment Development and Evaluation. GRADE working group. GRADE. Available at:. Accessed April 15, 2013. http://www.gradeworkinggroup.org/publications/JCE_series.htm.
16. Wikipedia. Typical antipsychotic. Wikipedia, Free Encycl. 2014. Available at:. Accessed July 8, 2014. http://en.wikipedia.org/wiki/Typical_antipsychotic.
17. Higgins J., Altman D. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008] 2008, The Cochrane Collaboration, Available from www.cochrane-handbook.org. Accessed April 21, 2015. J.P. Higgins, S. Green (Eds.).
18. Guyatt G., Oxman A., Vist G., et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011, 64:407-415.
19. Deeks J., Higgins J., Altman D. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) 2011, The Cochrane Collaboration, Available from www.cochrane-handbook.org. Accessed April 21, 2015. J.P. Higgins, S. Green (Eds.).
20. Hamilton L., Bennett J. The use of trifluoperazine in geriatric patients with chronic brain syndrome. J Am Geriatr Soc 1962, 10:140-147.
21. Sugerman A., Williams B., Alderstein A. Haloperidol in the psychiatric disorders of old age. Am J Psychiatry 1964, 120:1190-1192.
22. Rada R., Kellner R. Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. J Am Geriatr Soc 1976, 24:105-107.
23. Barnes R., Veith R., Okimoto J., et al. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients. Am J Psychiatry 1982, 139:1170-1174.
24. Petrie W., Ban T., Berney S., et al. Loxapine in psychogeriatrics: A placebo- and standard-controlled clinical investigation. J Clin Psychopharmacol 1982, 2:122-126.
25. Stotsky B. Multicenter study comparing thioridazine with diazepam and placebo in elderly, nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984, 6:546-559.
26. Finkel S., Lyons J., Anderson R., Sherrell K. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatry 1995, 10:129-136.
27. Auchus A., Bissey-Black C. Pilot study of haloperidol, and placebo agitation in Alzheimer's disease. Neuropsychiatry Clin Neurosci 1997, 9:591-593.
28. Devanand D., Sackeim H.A., Marder K., et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's Disease. Am J Psychiatry 1998, 155:1512-1520.
29. De Deyn P., Rabheru K., Rasmussen A. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53:945-956.
30. Teri L., Logsdon R.G., Peskind E. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000, 55:1271-1277.
31. Kaneko T., Cai J., Ishikura T., Kobayashi M. Prophylactic consecutive administration of haloperidol can reduce the occurrence of postoperative delirium in gastrointestinal surgery. Yonago Acta Med 1999, 42:179-184.
32. Allain H., Dautzenberg P., Maurer K., et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl) 2000, 148:361-366.
33. Pollock B., Mulsant B., Rosen J., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002, 159:460-465.
34. Kalisvaart K., de Jonghe J., Bogaards M., et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: A randomized placebo-controlled study. J Am Geriatr Soc 2005, 53:1658-1666.
35. Tariot P., Schneider L., Katz I., et al. Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006, 14:767-776.
36. Wang W., Li H., Wang D., et al. Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: A randomized controlled trial. Crit Care Med 2012, 40:731-739.
37. Molsa P., Marttila R., Rinne U. Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 1995, 91:159-164.
38. Wood L., Egger M., Gluud L., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ 2008, 336:601-605.
39. Brant R. Inference for proportions: Comparing two independent samples Available at:, Accessed July 8, 2014. http://www.stat.ubc.ca/%7Erollin/stats/ssize/b2.html.
40. Guyatt G., Oxman A., Kunz R., et al. GRADE guidelines: 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011, 64:1283-1293.
41. Public Health Advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances US Food and Drug Administration, Available at:, Accessed June 12, 2013. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm.
42. Kales H., Zivin K., Kim H., et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011, 68:190-197.
43. Alessi-Severini S., Dahl M., Schultz J., et al. Prescribing of psychotropic medications to the elderly population of a Canadian province: A retrospective study using administrative databases. PeerJ 2013, 1:e168.